The evolution of gene therapy has led to the development of promising new therapeutic approaches. This NeuroView will introduce the variety of delivery vehicles currently available for gene therapy, a range of preclinical strategies for tackling major diseases of the nervous system, the clinical limitations, and ethical considerations.
Gene Therapy Grows Up
The concept of gene therapy for human diseases gained momentum in the 1980s but was initially met by fear of changing the human genome and creating new infectious agents. As fears were lessened through new regulatory procedures, inventive spirits in academia and biotechnology entered a stage of high enthusiasm in the 1990s. The explosion in identification of disease-associated genes and generation of genetically authentic animal models propelled this optimism, and astounding therapeutic successes in different animal models suggested that the timeline for translation into clinical practice might be years, not decades. Many human trials later, the reality set in that this field, like others in medicine, was confounded by biological differences between animal models and patients.
By the new millennium, practitioners of the art had reached a sober conclusion that translation of gene therapy into the clinic faced considerable challenges, namely scaling up delivery from small animals to humans, unexpected toxicity and immunogenicity of some vector systems in humans, and integrative oncogenesis of vectors. Gene therapists resolutely continued to improve gene transfer vectors to enhance the efficiency and safety of in vivo and ex vivo gene transfer. Today, the ''new gene therapy'' includes not only genes, but also oligonucleotides (RNA and DNA) and a variety of delivery vehicles (nanoparticles, peptides, liposomes, virus vectors, and cells; Figure 1) . A new wave of clinical trials utilizing some of these improved gene transfer vectors is showing very promising results (for a review on clinical applications, see Gray et al., 2010) .
Vehicles and Routes for Genetic
Change A wide variety of delivery vehicles are available for gene and/or oligonucleotide delivery into the nervous system, including virus vectors, cells, liposomes, peptides, antibodies, and nanoparticles ( Figure 1 ). Most preclinical and clinical studies in the nervous system currently use AAV vectors, which provide longterm transgene expression and have an established safety record, albeit limited transgene capacity. Oncolytic HSV-1 is well suited for brain tumor therapy, while nonreplicating HSV-1 can enter a state of latency in neurons with continued transgene expression. Lentivirus vectors, which can either integrate or remain episomal in the genome of nondividing cells, show great promise and have a larger cargo capacity (Gray et al., 2010) . All these viral vectors have demonstrated safety and improvements in disease scores in some clinical trials, but the small number of patients and openlabel nature of most of these trials preclude any definitive conclusions on efficacy. Ongoing efforts to deliver short nucleic acids are focused on designing new liposome ''capsules'' and other types of nanoparticles and/or artificial delivery vehicles (Lares et al., 2010) .
Although in some diseases focal gene delivery may be adequate, global delivery within the nervous system is usually required ( Figure 1B ). The distribution of delivery vehicles within the brain can be enhanced by convection delivery, where infusion occurs under constant pressure over a prolonged period. Migratory cells, including hematopoietic cells, neuroprecursor cells, induced pluripotent stem (iPS) cells, mesenchymal stromal cells, and olfactory ensheathing glia can also be used to deliver gene products to wide areas in the brain. Some delivery vehicles and therapeutic proteins can even be distributed within the brain by axonal transport (e.g., Passini et al., 2003) .
The high vascularization of the brain offers another route for global distribution. Though access is limited by the bloodbrain barrier (BBB) in normal adult brain, access is increased somewhat in disease states, injury, and tumors, as well as in the more immature brain. Initial approaches involved PEGylated immunoliposomes formulated with monoclonal antibodies specific for transferrin and insulin receptors, to mediate transcytosis across the BBB. New stealth vectors, such as chimeric recombinant molecules carrying a therapeutic protein or RNA conjugated to antibodies, transcytosis ligands, or nanoparticles, can also be effective at crossing the BBB (Lares et al., 2010) . Recently, AAV9 vectors also joined this highly exclusive BBBtraversing club. Another route of entry is the blood-CSF barrier ( Figure 1B ), which has been used to achieve widespread AAV-mediated transgene delivery in neonatal mice, but with more limited transduction in adults (Passini et al., 2003) . Unfortunately, vector delivery into the CSF and blood has a higher risk of inflammatory immune response as compared to direct delivery into the brain parenchyma. An interesting alternative is to engineer brain microcapillary endothelium, choroid plexus, or ependymal cells to secrete therapeutic proteins into the brain and CSF.
Changing Genetic Constituency Replace or Correct Defective Genes
In cases of a mutational deficiency (recessive disease), the goal is to replace, correct, or use substitute genes to regain normal function. This can be achieved with the use of viral vectors or DNA cassettes to express the normal gene in the brain, or with hematopoietic stem cells (HSCs) from the patient, which are genetically modified ex vivo and then reintroduced. Macrophages derived from the newly modified HSCs migrate into the diseased CNS, where they differentiate into resident microglia expressing the normal protein. Other promising, though less efficient, approaches involve direct gene correction through homologous recombination, transplicing of correct gene sequences onto mutant messages during transcription, and use of antisense oligonucleotides to suppress some splice sites or favor new ones in mutant precursor mRNAs to generate functional proteins. A dramatic new approach in vision is to use substitute proteins from lower organisms, e.g., the opsins, to restore light-sensing defects in eye diseases, sometimes by turning retinal ganglionic cells into light-sensing cells (see Roy et al., 2010) . Suppress Defective Genes Other hereditary diseases are caused by mutations producing a defective protein that itself causes disease (dominantnegative condition). In this case, one wants to selectively suppress expression of the defective transcript while leaving the normal transcript intact, e.g., through siRNAs specific to the mutant mRNA. Downregulation of both mutant and wildtype alleles may be compatible with therapeutic response, if lowering the normal Figure 1 . Combinations of Gene, Vector, Oligonucleotide, and Cell Delivery for Diseases of the Nervous System (A) Gene composition or expression in cells can be modified by introduction of DNA, RNA oligonucleotides (e.g., siRNA, microRNA), and genes encoded in virus vectors. These are typically delivered by injection into the brain parenchyma (P) or ventricles (Ve), the spinal cord, or the eye. DNA and/or RNA can also be used to genetically modify (GM) cells for delivery through injection or vascular infusion. These different vehicles-genes (G), vectors (V), oligonucleotides (O), and cells (C)-can be combined in different modalities, including ''jump starting'' primary and stem cells to take on specific phenotypes through transcriptional regulation. (B) Delivery to extended brain regions can be achieved by injection into the ventricles (Ve) or by modifying the ventricle lining to produce substances into the CSF. With direct delivery into the brain parenchyma (P), the range can be expanded by using convection enhanced delivery; by injecting into regions with extensive neuronal networks (e.g., the thalamus); and by using migratory cells or selectively replicating virus vectors. Access can also be gained through the vasculature across the blood-brain barrier or the blood-CSF barrier by using hematopoietic cells and vectors; by coupling peptides, antibodies, or other agents to GVOs to facilitate transcytosis; or by osmotic disruption of tight junctions between cells lining the barrier to temporarily increase permeability. This panel is adapted with permission from Figure 5 of Abbott et al. (2006) , Nature Reviews Neuroscience 7, 41-53. gene product can be tolerated. Suppression can also be achieved by delivery of microRNAs, although these often have off-target effects (Lares et al., 2010) . Target the Downstream Symptoms Many gene therapy strategies are directed toward common diseases of unknown etiology, where the approach is to target the disease symptoms in hopes of arresting or reversing the degenerative process. Examples include suppressing endogenous Nogo-A, a protein that inhibits nerve regeneration in multiple sclerosis (Yang et al., 2010) , or suppressing angiogenesis in macular degeneration by delivery of antisense RNA to VEGF mRNA or decoy VEGF receptors (Roy et al., 2010) . The delivery of neurotrophic factors, e.g., nerve growth factor (NGF) for Alzheimer disease (AD), glial-derived neurotrophic factor (GDNF), neurturin or brain-derived neurotrophic factor (BDNF) for Parkinson disease (PD), and insulinlike growth factor type 1 (IGF-1) for amyotrophic lateral sclerosis (ALS), has also shown promise. In AD, efforts have also focused on decreasing extracellular Ab amyloid load by expressing Ab-specific single-chain antibodies or the Ab-degrading protease neprilysin (Ryan et al., 2010; Lebson et al., 2010) and by regulating Ab generation (in mice) by accelerating cholesterol turnover (Hudry et al., 2010) . These approaches have the potential to arrest or reverse the degenerative process, which is not possible with current medical treatment.
Parkinson disease has been the target of numerous therapeutic strategies. Though animal studies indicate that certain growth factors can restore dopaminergic function (e.g., Kells et al., 2010) , this promise has yet to be realized in clinical trials, raising questions about the extent to which these animal models accurately represent the molecular etiology of the disease. Other approaches involve augmentation of dopamine synthesis by gene delivery of biosynthetic enzymes (Bjorklund and Kordower, 2010) or suppression of abnormal subthalamic activation by focal delivery of the biosynthetic enzyme for the inhibitory neurotransmitter GABA (Feigin et al., 2007) , offering potential prolongation of L-dopa-like therapeutic effects. It is also now possible to convert patient fibroblasts into replacement dopaminergic neurons, although they may also succumb to the degenerative environment. Finally, RNAi-mediated suppression of a-synuclein synthesis seems an obvious approach; however, at least one study indicates that either up-or downregulation of a-synuclein can produce degenerative changes in the brain (Gorbatyuk et al., 2010) . Eliminate Tumor Cells A huge effort has been devoted to using gene therapy to extend the life span of brain tumor patients. Given the urgency for treatment, with glioblastoma patients typically dying within a year of diagnosis, there has been less hesitation to ''pull out the big guns''-replicating virus vectors (Kaur et al., 2009 ). The range of viruses explored in this assault is truly astounding, including a range of human and animal viruses. The goal is to use modified viruses that replicate selectively in tumor cells and spare normal brain cells. Oncolytic viruses can also be armed with a variety of genes to kill or suppress tumor growth (Kaur et al., 2009) , including enzymes that convert prodrugs to chemotherapeutic agents within the tumor, cytokines that enhance the immune response to tumor antigens, and both antiangiogenic and apoptotic factors. Delivery systems are being explored to expand the range of gene delivery, including use of normal migratory cells that naturally home to tumor foci in the brain and/or can be endowed with tumor-targeting ligands. These cells can be genetically modified to express therapeutic genes with a ''bystander effect'' (stealth bombers) or carry oncolytic viruses within them (Trojan horses). Although the dire prognosis for brain tumor patients calls for strong medicine, the possibility of generating new human-transmissible virus species requires strong regulatory oversight.
Promising Near-Therapies Within the nervous system, several therapeutic targets seem close to achieving benefit in clinical trials, including certain forms of blindness, lysosomal storage diseases, and PD. The dramatic success in restoring some light sensitivity by vector-mediated delivery of a missing retinal enzyme to retinal pigment epithelium in patients has been a huge incentive to gene therapy (Roy et al., 2010) . However, out of all causes of vision loss that might be potentially amenable to gene therapy, those with unchecked degeneration or immune inflammatory reactions will probably not respond to these therapies long-term. Lysosomal storage diseases may be amenable to treatment by either direct injection of virus vectors or transplantation of a patient's hematopoietic stem cells genetically modified to express the missing protein . Unfortunately, there is sometimes a need for very early treatment to prevent unrecoverable neuronal loss, with limited precedent for the safety of vectors in children. Finally, in PD, delivery of genes involved in synthesis of dopamine in the striatum or GABA in the subthalamic nucleus offer promise for relief of motor symptoms. However, it is not clear how long such interventions will be effective, as compared to DBS, given the ongoing neuronal degeneration. These strategies also may not ameliorate deficits in other brain regions associated with depression and dementia.
Limitations and Ethical Considerations Timing and Response
As with other medical treatments, these approaches should be viewed as a means to reduce symptoms and extend viable life span, rather than as a cure. Presently, it is impossible to deliver a gene to all affected cells, and usually some irreversible damage has occurred prior to diagnosis and treatment. The outcome of gene therapy will probably depend on factors such as the stage of disease progression at the time of intervention and the stability of treatment. For AAV vectors tested in nonhuman primate brains, transgene expression remains stable for at least 8 years. However, the life span of humans is now in the 80+ years range, and readministration may be necessary. Critical to establishing the need for ''refresher'' therapy will be the availability of biomarkers to report on the status of the nervous system, and vector readministration could be hindered by potential immunologic neutralization of the delivery vehicle.
The main risk associated with integrating vectors (e.g., lentivirus vectors) is the potential for disrupting or activating gene functions, with the greatest risk being tumor formation. This risk is shared with stem cells, which are susceptible to spontaneous mutations that can drive them down the oncogenic pathway. Furthermore, in the current state-of-theart technology, there is no regulation of transgene expression and thus no way to adjust levels of the gene product to achieve optimal therapeutic intervention, and if toxic effects ensue there is no way to stop expression. In some vectors, a suicide (prodrug-activating) gene is included so cells producing the transgene can be killed by prodrug administration in the case of adverse events.
Risk versus Benefit
Given that gene therapy modalities are experimental at this stage, the patients and their families need to be fully informed about the nature of their illness and the therapeutic strategy that will be tested in them. Informed consent is a very serious and critical process where the patient, or parents, must weigh the possible risks and benefits of the procedure. Clearly, if the illness is life threatening, or neuronal loss is unremitting, the patient may be willing to take on a greater degree of risk of adverse effects. Gene therapy procedures are also often applied when the disease is well advanced, which may limit their potential effectiveness. In many cases the patient and family may agree to participate solely to help develop promising therapies for future patients, who may even be their own family members. In less severe diseases, the less invasive nature of many gene therapy paradigms may be preferable over surgical procedures, though gene therapy may address only a subset of symptoms or prolong life but with considerable remaining disabilities.
The appeal of gene therapy is the promise of more effective treatment for diseases that have defied other conventional medical modalities. With apparent clinical successes in blindness, X-linked adrenoleukodystrophy, and PD, we can anticipate renewed efforts at the research level to improve delivery modalities, and increasing numbers of clinical trials as everyone becomes more accustomed to weighing the potential risks and benefits.
